Related Experiment Video

Updated: May 25, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

The therapeutic potential of GPR119 agonists for type 2 diabetes

Takahide Ohishi1, Shigeru Yoshida

  • 1Drug Discovery Research , Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, Japan. takahide.ohishi@astellas.com

Expert Opinion on Investigational Drugs
|February 2, 2012
PubMed
Abstract

Insights

GPR119 agonists show promise for treating type 2 diabetes mellitus (T2DM) by improving pancreatic beta cell function and enhancing insulin secretion. These agents offer a potential new therapeutic avenue for managing T2DM.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) is a growing global health concern characterized by pancreatic beta cell dysfunction.
  • G protein-coupled receptor 119 (GPR119) is a promising therapeutic target for T2DM, expressed in pancreatic beta cells and enteroendocrine cells.
  • Existing treatments highlight the need for novel agents to improve beta cell function in T2DM.

Purpose of the Study:

  • To review the function of GPR119 and advancements in GPR119 agonist discovery since 2002.
  • To discuss the significance of GPR119 agonists in glycemic control for T2DM.
  • To evaluate the therapeutic potential of GPR119 agonists in T2DM management.

Main Methods:

  • Literature review of studies on GPR119 function and agonist development.
  • Analysis of in vitro data on GPR119 agonist effects on cAMP levels and hormone secretion.
  • Examination of preclinical data from T2DM rodent models assessing glucose levels and beta cell function.

Main Results:

  • GPR119 agonists stimulate glucose-dependent insulin release and incretin hormone secretion (GLP-1).
  • In vitro studies show GPR119 activation increases intracellular cAMP levels.
  • Preclinical studies demonstrate that GPR119 agonists reduce blood glucose and preserve pancreatic beta cell function in T2DM models.

Conclusions:

  • GPR119 agonists are expected to preserve pancreatic beta cell function through enhanced insulin secretion and promoter activity.
  • These agonists offer significant clinical benefits for patients with T2DM.
  • Both preclinical and clinical evidence suggest GPR119 agonists represent a promising class of anti-diabetic drugs.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: